Examining Lung Proteins in Patients with Pneumonia
Biomarkers and Protein Mass Expression Profiles in Bronchoalveolar Lavage From Patients With Lung Infiltrates
This study is testing lung fluid samples from pneumonia patients to see if certain proteins can help identify the causes of their lung issues and improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 750 (estimated) |
| Ages | 3 Years to 99 Years |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT00077909 on ClinicalTrials.gov |
What this trial studies
This study analyzes bronchoalveolar lavage (BAL) fluid from patients with pneumonia to identify protein and peptide patterns associated with different types of pulmonary diseases. By using advanced proteomic techniques, the research aims to discover biomarkers that can help determine the causes of lung inflammation and infection. Patients undergoing bronchoscopy at the NIH Clinical Center will provide BAL samples, which will be analyzed to improve understanding of the host response to pneumonia and potentially guide treatment options.
Who should consider this trial
Good fit: Ideal candidates include patients undergoing diagnostic bronchoscopy for clinical reasons who consent to participate in the study.
Not a fit: Patients who do not wish to participate in the proteomic analysis or chart review will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of specific biomarkers that improve diagnosis and treatment of pneumonia.
How similar studies have performed: While similar studies have explored biomarkers in pneumonia, this approach using advanced proteomic analysis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: * All eligible patients undergoing diagnostic bronchoscopy who provide consent for proteomic analysis of BAL fluid supernatant and chart review of patient characteristics will be included in this study. * A parent/guardian may provide consent for a child age 17 or under and a Legally Authorized Representative (LAR) may provide consent for adults unable to consent. EXCLUSION CRITERIA: Patients undergoing bronchoscopy but not wanting to participate with either the chart review or the proteomic analysis of BAL fluid supernatant will be excluded.
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Anthony F Suffredini, M.D. — National Institutes of Health Clinical Center (CC)
- Study coordinator: Gloria Y Pastor, R.N.
- Email: gloria.pastor@nih.gov
- Phone: (301) 402-3484
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.